Db.V

The company's capital structure is characterized by a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.34, suggesting the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company reported negative net income of -2.92 million CAD and negative operating income of -0.14 million CAD, indicating a lack of profitability in the most recent period. Return on equity and return on assets are both negative, at -4.69% and -2.06% respectively, which is below the typical performance of the pharmaceutical industry.

The company's profitability metrics are significantly below the industry median, with a negative net income and operating income. This suggests that the company is not currently generating sufficient revenue to cover its operating costs and is not delivering returns to shareholders. The gross profit margin is also low, at 21.4%, which is below the industry average for pharmaceutical companies. The company's operating cash flow is positive at 7.46 million CAD, but this is not sufficient to offset the negative net income, indicating that the company is not generating enough cash from operations to sustain its current level of operations.

The company's revenue is not segmented by geographic region or product line in the provided data, making it difficult to assess the geographic exposure or the contribution of different segments to the overall revenue. However, the lack of segmentation data suggests that the company may have a concentrated revenue base, which could pose a risk if a particular market or product line underperforms. The company's growth trajectory is uncertain, as the provided data does not include historical revenue figures or future outlook projections. The company's negative net income and operating income suggest that it is not currently experiencing growth and may be facing challenges in expanding its operations.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity constraints in the near term. The company's capital expenditure of -1.98 million CAD indicates a reduction in capital spending, which could be a sign of financial prudence or a lack of investment opportunities. The company's dilution risk is assessed as low, with no near-term pressure expected, and no dilution sources identified in the provided data.

Recent events and filings do not provide specific details on the company's operations or financial performance. The company's financial snapshot indicates a negative net income and operating income, which may be a result of increased costs or decreased revenue. The company's operating cash flow is positive, but this is not sufficient to offset the negative net income, indicating that the company is not generating enough cash from operations to sustain its current level of operations. The company's free cash flow is positive at 2.58 million CAD, which suggests that the company has some flexibility in its cash management.

The company's recent financial performance and risk assessment suggest that it is facing challenges in maintaining profitability and liquidity. The company's negative net income and operating income indicate that it is not currently generating sufficient revenue to cover its operating costs and is not delivering returns to shareholders. The company's liquidity position is assessed as medium, with a current ratio of 1.34, which suggests that the company has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's debt-to-equity ratio of 0.71 indicates a moderate reliance on debt financing, which could pose a risk if the company is unable to service its debt obligations.